Compounds > mefloquine hydrochloride

mefloquine hydrochloride and lumefantrine

mefloquine hydrochloride has been researched along with lumefantrine in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (77.78)29.6817
2010's2 (22.22)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adrián, F; Anderson, P; Brinker, A; Caldwell, JS; Chatterjee, A; Gray, NS; Henson, K; Janes, J; Kato, N; Kuhen, K; Matzen, JT; McNamara, C; Nagle, A; Nam, TG; Plouffe, D; Schultz, PG; Trager, R; Winzeler, EA; Yan, SF; Zhou, Y1
Du, LP; Li, MY; Tsai, KC; Xia, L; You, QD1
Anstey, NM; Brockman, A; Chalfein, F; Cheng, Q; Kenangalem, E; Piera, K; Prasetyorini, B; Prayoga, P; Price, RN; Russell, B; Sugiarto, P; Suwanarusk, R; Tjitra, E1
Bertaux, L; Bogreau, H; Bouchiba, H; Garnotel, E; Kraemer, P; Parzy, D; Pradines, B; Rogier, C; Savini, H; Simon, F1
Anstey, NM; Chalfien, F; Hasugian, AR; Kenangalem, E; Marfurt, J; Penttinen, PM; Piera, KA; Price, RN; Purba, HL; Ratcliff, A; Russell, B; Siswantoro, H; Tjitra, E; Wuwung, RM1
Almeras, L; Amalvict, R; Baret, E; Briolant, S; Fusaï, T; Henry, M; Parquet, V; Pradines, B; Rogier, C; Torrentino-Madamet, M1
Masseno, V; Muriithi, S; Nzila, A1
Sen, S; Sinha, N1
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y1

Other Studies

9 other study(ies) available for mefloquine hydrochloride and lumefantrine

ArticleYear
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
    Proceedings of the National Academy of Sciences of the United States of America, 2008, Jul-01, Volume: 105, Issue:26

    Topics: Animals; Antimalarials; Cluster Analysis; Computational Biology; Drug Evaluation, Preclinical; Drug Resistance; Folic Acid Antagonists; Malaria; Models, Molecular; Parasites; Plasmodium falciparum; Reproducibility of Results; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase

2008
The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents.
    Bioorganic & medicinal chemistry letters, 2004, Sep-20, Volume: 14, Issue:18

    Topics: Anti-Arrhythmia Agents; Models, Biological; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical

2004
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:3

    Topics: Animals; Antimalarials; Chloroquine; Humans; Inhibitory Concentration 50; Life Cycle Stages; Parasitic Sensitivity Tests; Plasmodium falciparum; Plasmodium vivax; Schizonts; Time Factors

2008
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:6

    Topics: Animals; Antimalarials; Atovaquone; Comoros; Drug Resistance; France; Genotype; Humans; Malaria, Falciparum; Male; Parasitic Sensitivity Tests; Plasmodium falciparum; Proguanil; Travel; Treatment Failure

2008
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3

    Topics: Adolescent; Age Distribution; Amodiaquine; Animals; Antimalarials; Chloroquine; Confidence Intervals; Drug Resistance; Drug Tolerance; Female; Follow-Up Studies; Humans; Inhibitory Concentration 50; Male; Outpatients; Parasitemia; Plasmodium vivax; Prospective Studies; Recurrence; Rural Health; Time Factors; Treatment Failure; Treatment Outcome

2009
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:6

    Topics: Animals; Antimalarials; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plasmodium falciparum; Pyrroles

2009
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:7

    Topics: Adjuvants, Pharmaceutic; Animals; Antimalarials; Parasitic Sensitivity Tests; Plasmodium falciparum; Probenecid; Verapamil

2009
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:2

    Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship

2011
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
    Science (New York, N.Y.), 2011, Dec-09, Volume: 334, Issue:6061

    Topics: Animals; Antimalarials; Cell Line, Tumor; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance; Erythrocytes; Humans; Imidazoles; Liver; Malaria; Mice; Mice, Inbred BALB C; Molecular Structure; Piperazines; Plasmodium; Plasmodium berghei; Plasmodium falciparum; Plasmodium yoelii; Polymorphism, Single Nucleotide; Protozoan Proteins; Random Allocation; Small Molecule Libraries; Sporozoites

2011